

## Conflict of Interest Statement

### **Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial**

**Conflict of Interest Statements:** Joy TR has received speakers' honoraria from Merck, Novo Nordisk, Eli Lilly, Boehringer Ingelheim, Janssen, Astra Zeneca; served as an advisory board member or consultant to Amgen, Sanofi, Novo Nordisk, Merck, and participated in clinical trials with Amgen and Astra Zeneca. Beaton MD has served as an advisory board member or consultant for Abbvie, Allergan and Takeda, and participated in clinical trials with Gilead and Intercept. The remaining authors have no conflict of interest to report

This can be found on page 2 of the manuscript.

#### Corresponding Author:

Dr. Melanie D. Beaton, Associate Professor, Department of Medicine, Division of Gastroenterology, London Health Sciences Centre, 339 Windermere Road, London, ON, N6A 5A5, Canada. [melanie.beaton@lhsc.on.ca](mailto:melanie.beaton@lhsc.on.ca)

**Telephone:** +1-519-663-3344

**Fax:** +1-519-663-3220